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Abstract
Tardive dyskinesia (TD), characterized by oro-buccal-lingual stereotypy, can manifest in the form of akathisia, dystonia, tics, tremor, chorea, or as a combination of
different types of abnormal movements. In addition to movement disorders (including involuntary vocalizations), patients with TD may have a variety of sensory
symptoms, such as urge to move (as in akathisia), paresthesias, and pain. TD is a form of tardive syndrome—a group of iatrogenic hyperkinetic and hypokinetic
movement disorders caused by dopamine receptor-blocking agents. The pathophysiology of TD remains poorly understood, and treatment of this condition is often
challenging. In this update, we provide the most current information on the history, nomenclature, etiology, pathophysiology, epidemiology, phenomenology,
differential diagnosis, and treatment of TD.
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History and Definitions
TD is a group of delayed-onset iatrogenic movement disorders of
various phenomenology caused by dopamine receptor-blocking agents,
also referred to as neuroleptics. In some cases, the movement disorder
may be accompanied by sensory phenomenon such paresthesias, pain
and an inner urge to move. Neuroleptic medications were introduced
in the early 1950s and revolutionized the treatment of schizophrenia
and other psychiatric disorders. Just a few years later, however,
neuroleptics were recognized as a cause of abnormal involuntary
movements. The first report of orofacial stereotypic involuntary
movements, referred to as ‘‘paroxysmal dyskinesia,’’ in a patient
treated with the phenothiazine derivative megaphen was published in
1957.1
The term ‘‘tardive dyskinesia’’ (TD) was first introduced in 1964 by
Faurbye, highlighting the delay between the initiation of treatment with
the offending drug and the onset of the abnormal movements (hence, the
name ‘‘tardive’’).2 The term is now used to define any tardive hyperkinetic
movement disorder, such as stereotypy, akathisia, dystonia, tremor, tics,
chorea, and myoclonus. On the other hand, some physicians reserve the
term TD exclusively for oro-bucco-lingual stereotypy, which has caused
confusion in the medical literature. Because many patients present with a
combination of different phenomenologies, which may include a move-
ment disorder as well as sensory symptoms, the term ‘‘tardive syndrome’’ is
more appropriate when referring to all tardive disorders, manifested by
any combination of hyperkinetic or hypokinetic movement disorders, as
well as sensory symptoms that may be phenomenologically distinct but
sharing the same etiological background (recent exposure to dopamine
receptor-blocking agents [DRBAs]). We suggest that the term ‘‘classic
tardive dyskinesia’’ should be used for oro-bucco-lingual stereotypy when it
manifests as an isolated or predominant tardive syndrome.3
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According to the Diagnostic and Statistical Manual of Mental
Disorders, 4th ed. (DSM-IV), TD develops during exposure to a
DRBA for at least 3 months (or 1 month in patients age 60 years or
older) or within 4 weeks of withdrawal from an oral medication (or
within 8 weeks of withdrawal from a depot medication).4 The disorder
should persist for at least 1 month after discontinuation of an offending
drug to qualify as TD. Some experts consider exposure to DRBAs
within 1 year prior to the onset of tardive syndrome as being causally
related. Withdrawal emergent syndrome was first described in 1973 by
Polizos et al5 as choreic movements in children after abrupt discon-
tinuation of long-term use of an antipsychotic drug. The symptoms
usually manifest during the first few days or weeks after discontinuation
of the offending DRBA.
Etiology
TD results from chronic exposure to DRBAs, such as some
antipsychotics (typical and atypical neuroleptics), tricyclic antidepres-
sants (e.g., amoxapine), and antiemetics and other medications used
for gastrointestinal disorders (e.g., metoclopramide and promethazine)
(Table 1). The first generation ‘‘typical’’ neuroleptics with high
dopamine D2 receptor occupancy have been reported to have a
higher risk of causing TD than the second- or third-generation
medications, often referred to as ‘‘atypical’’ antipsychotics, with low D2
receptor occupancy, such as clozapine and quetiapine. It is now well
recognized, however, that even atypical antipsychotics can cause TD.6
There are also relatively rare cases of movement disorders, clinically
indistinguishable from DRBA-induced TD, that have been reported to
be associated with the use of antidepressants, such as certain selective
serotonin reuptake inhibitors (SSRIs) or selective serotonin norepi-
nephrine reuptake inhibitors (SNRIs).7,8 The mechanism of TD
caused by SSRIs or SNRIs is unclear. Some authors have hypo-
thesized that increased levels of serotonin might inhibit striatal neurons
and produce a antidopaminergic effect similar to DRBAs.7,8 Further
epidemiologic and animal model studies are needed to clarify the role
of SSRIs in TD. Rare cases of TD were also associated with lithium.9
Calcium channel blockers, such as cinnarizine and flunarizine, are
relatively common causes of tardive syndromes in some countries.10
Pathophysiology
Pathophysiology of TD remains poorly understood, but it is believed
to be the result of chronic blockade of dopamine receptors, particularly
D2 and possibly D3, by DRBAs. ‘‘Typical’’ antipsychotics tightly bind
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and remain attached to D2 receptors for a longer time (a few days) than
‘‘atypical’’ agents. Therefore, they have a stronger antipsychotic effect
but much higher propensity to cause TD than ‘‘atypical’’ antipsychotic
drugs, which have a relatively low degree of D2 receptor antagonism
and rapid (12–24 hours after a single dose) dissociation from the D2
receptors, thus presumably explaining the lower risk of TD.11 In
addition to dopamine, other neurotransmitter receptors may be
important in determining a drug’s propensity to facilitate TD,
especially 5-hydroxytryptamine 2 (5-HT2) receptors that are widely
distributed in the striatum and are thought to be involved in
modulating motor activity by interaction with dopaminergic neuro-
transmission.12 High 5-HT2 receptor-blocking activity of ‘‘atypical’’
antipsychotics, combined with their low D2 receptor occupancy, has
been thought to be protective against TD because of a relative lack of
D2 receptor upregulation.
12,13
One of the most prominent theories about TD pathogenesis is that
chronic exposure to the neuroleptics results in D2 receptor upregula-
tion with postsynaptic dopamine receptor supersensitivity. This theory
is difficult to prove but is supported by the common observation that
increased DRBA dose can temporarily alleviate the symptoms of TD,
and the abrupt withdrawal of an offending drug can exacerbate or
even cause TD. Because D2 receptors are inhibitory receptors
expressed on medium-spiny neurons that project onto the indirect
pathway, their hypersensitivity can result in disinhibition of the globus
pallidus internus and subthalamic nucleus, producing a variety of
hyperkinetic movement disorders.14 On the other hand, the dopamine
receptor supersensitivity and receptor upregulation theory cannot
explain why TD often persists for years or even decades after
discontinuation of the offending DRBA, since theoretically the
dopamine receptors lacking continuous blockade would be expected
to decrease in numbers due to downregulation.
Another theory of TD pathogenesis, supported by animal studies
(mice, rats, primates), proposes that damaged or dysfunctional striatal
c-aminobutyric acid (GABA)-containing neurons lead to GABAergic
hypofunction and degeneration of the striatal fast-spiking GABAergic
interneurons that regulate balance between direct and indirect basal
ganglia pathways.15–17
According to the recently proposed ‘‘maladaptive synaptic plasti-
city’’ hypothesis, D2 receptor hypersensitivity and degenerative
changes in the neurons caused by increased oxidative stress can result
in secondary effects on the synaptic plasticity of glutamatergic synapses
on striatal interneurons, causing imbalance between direct and indirect
basal ganglia pathways and thus producing abnormal output to the
sensorimotor cortex.14 Maladaptive cortical synaptic plasticity,
coupled with abnormal basal ganglia output, may lead to the
formation of miscoded motor programs and abnormal movements.
The ‘‘neurodegenerative hypothesis’’ of TD is supported by the
irreversibility of the symptoms after discontinuation of the offending
drug.18 Proponents of this hypothesis suggest that neuroleptics could
increase lipid peroxidation and free radical formation, leading to the
neuronal damage and therefore degeneration of the different
neurotransmitter systems. Structural changes in the brain, including
neuronal loss and gliosis in the basal ganglia after prolonged exposure
to neuroleptics, were identified in animal studies and postmortem
neuropathological examinations of the brains of TD patients.19 The
neurodegenerative hypothesis eventually merged with the oxidative
stress hypothesis. Accordingly, blockade of dopamine receptors leading
to increased dopamine turnover is thought to be associated with
increased free radical formation by monoamine oxidase and also with
auto-oxidation of dopamine molecules into free radicals and
quinines.18,20 Increased production of free radicals, coupled with
impairment of the antioxidant system leading to increased oxidative
stress, was reported with chronic neuroleptic administration.21 This
oxidative stress hypothesis20,22 is supported by the finding that plasma
activity of manganese superoxide dismutase, one of the main enzymes
involved in the antioxidant defense mechanism, is elevated in TD
patients compared with the subjects on neuroleptics without TD or
normal controls.23 The level of enzyme activity in TD patients
correlated with TD clinical symptom severity. A polymorphism in the
superoxide dismutase gene was also associated with TD.20
Interestingly, most patients taking antipsychotic medications for
years do not develop TD, and patients with TD caused by exactly the
same medication regimen might have a very broad range of TD
severity and phenomenology. These observations might be explained
by individual, possibly genetic, susceptibility for TD.14,20,24 Several
gene candidates have been implicated in the predisposition for TD,




27 manganese superoxide dismutase,23
catechol-O-methyltransferase (COMT),28 and several other genes with
various degrees of association with TD.14,20 In addition, cytochrome
P450 (CYP2D6), which affects drug metabolism, may influence the
risk for TD.29 A meta-analysis of 20 studies from 1976 to 2007
estimated pooled odds ratios (ORs) of TD associated with COMT,
DRD2, and MnSOD gene polymorphisms.28 Among 382 TD and 707
non-TD patients exposed to DRBAs, two variants of the COMT gene
were found to be protective against TD (ORs 0.63 and 0.66). Analysis
of MnSOD gene polymorphism in 134 TD and 546 non-TD patients
identified two protective gene variants with ORs of 0.37 and 0.49.
Two DRD2 gene variants were found to predispose for TD (ORs 1.30
and 1.80) in the pooled population of 297 TD and 467 non-TD
patients. An analysis of DRD3 gene polymorphism in a pooled sample
of 317 TD and 463 non-TD patients identified the DRD3gly gene
variant as a factor increasing susceptibility for TD (pooled OR 1.33).25
A 5-HT2A gene variant (T102C) was associated with a higher risk of
developing TD in 221 schizophrenic patients (OR 0.44).27
Epidemiology
TD prevalence is estimated to be 20–50% of all patients treated with
neuroleptics, but it varies among different age groups and published
studies, with prevalence increasing with advanced age.4 The largest
review involving 56 studies and 34,555 subjects treated with
neuroleptics, yielded an average TD prevalence of 20%.30 Although
TD prevalence in patients treated with metoclopramide has been less
studied, the published data indicate a prevalence ranging from less
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than 1% to 10%.31 The incidence of neuroleptic-induced TD is lower
among younger individuals (3–5% per year) and higher in middle-aged
and elderly patients, particularly women, reaching incidence rates as
high as 30% after 1 year of cumulative exposure to neuroleptics.
Incidence of TD was lower in patients treated with second-generation
neuroleptics (risperidone, olanzapine, quetiapine, amilsulpride, and
ziprasidone), with the total annual incidence rate ranging from 0.8% in
patients younger than 50 years to 5.3% in those older than 50 years.32
Although previous studies suggest that both genders are equally
susceptible to TD, postmenopausal women might have a higher risk of
developing TD.4 The latter observation might be explained by the fact
that estrogen modulates dopamine-mediated behaviors and exhibits an
antioxidant effect, thus potentially protecting against TD.20,33 TD is
the exception to the age-related increase in incidence of tardive
syndrome, which tends to occur more often in young male patients.
Besides age and gender, other less convincing demographic and
medical risk factors include African-American race,34 pre-existing
movement disorders, brain damage, cognitive impairment, total
DRBA load (composed of the dose and the duration of drug exposure),
mood disorder, presence of negative schizophrenia symptoms, alcohol
and drug abuse, and diabetes mellitus.35,36
A study of 100 patients with tardive syndromes reported the
following frequencies of different types of movement disorders: 72%
had oro-bucco-lingual dyskinesia (classic TD), 30% had tardive
tremor, 22% had tardive akathisia, 16% had tardive dystonia, and
4% and 1% had tardive tics and myoclonus, respectively; 35% of the
patients had a combination of two or more tardive syndromes.37
Clinical Course and Phenomenology of Tardive Syndromes
The symptoms of TD usually first appear after 1–2 years of
continuous exposure to a DRBA and almost never before 3 months.36
Severity of TD ranges from mild involuntary movements often
unnoticed by a patient to a disabling condition. TD has an insidious
onset; it usually evolves into a full syndrome over days and weeks,
followed by stabilization of the symptoms, and a chronic but waxing
and waning course. TD tends to persist for years or decades in the
majority of patients, even after elimination of the offending drug. In
some patients it can remit completely or partially a few years after
discontinuation of a causative medication or even while continuing
DRBA treatment. In one study, 33% of the patients experienced
remission of their TD 2 years after discontinuation of the offending
drug.38 Other studies, however, have reported much lower rates of
remission. In one study, only 5 out of 42 (12%) patients achieved
remission following discontinuation of DRBAs (for up to 6.7 years).39
Interpretation of spontaneous remission rates in TD patients who
continue treatment with DRBAs might be complicated by the fact that
DRBAs can suppress or mask the dyskinesia.35 The rate of remission of
TD without discontinuation of DRBAs was reported to be 2.5% per
year, which was only slightly higher than the remission rate following
discontinuation or reduction of the DRBA dose.35,40 Another study
found that permanent discontinuation of DRBAs in TD patients
increased the chance of remission by fourfold after 8.5 years of
follow-up (22% out of 54 patients withdrawn from DRBAs vs. 5.8%
from 52 patients who continued taking DRBAs).19 Several studies have
concluded that longer duration of exposure to DRBAs prior to
discontinuation decreases the chances of remission of TD.19 On the
other hand, TD may be precipitated by a dose reduction or sudden
withdrawal of neuroleptics, especially in children (withdrawal emer-
gent syndrome),41 with the symptoms manifesting during the first few
days or weeks after DRBA discontinuation. In contrast to other TD
syndromes, withdrawal emergent syndrome is typically encountered
almost exclusively in children and is self-limiting, typically completely
resolving over several weeks.
Tardive syndrome can manifest as a variety of phenomenologically
distinct abnormal movements or their combination. The spectrum of
tardive syndrome includes stereotypy, dystonia, akathisia, tics (tardive
tourettism), myoclonus, tremor, or chorea (Table 2). Besides these
iatrogenic hyperkinetic movement disorders, DRBA can also cause
other delayed-onset neurological conditions, such as drug-induced or
tardive parkinsonism and neuroleptic malignant syndrome.42,43
Classic TD (Video 1) manifests as involuntary stereotypic movements
in the oro-bucco-lingual region, such as lip smacking or pursing,
chewing, facial grimacing, and tongue movements inside the mouth or
tongue popping out; thus, it is often termed ‘‘oro-bucco-lingual
stereotypy.’’44 Patients with classic TD may also have stereotypic
movements involving the limbs or trunk; however, oro-bucco-lingual
stereotypy remains the leading phenomenology of this syndrome.
The term ‘‘tardive stereotypy’’ is often used to describe the seemingly
purposeful, repetitive, and coordinated movements sometimes giving
the appearance of ritualistic gestures or mannerisms (Video 2).45
Although oro-bucco-lingual stereotypy of classic TD is the most
common form of tardive stereotypy, some patients also have limb
stereotypies, manifested as repetitive foot tapping, complex stereotypic
piano-playing finger and toe movements, and hand rubbing. Trunk
stereotypy is typically manifested by repetitive rocking and swaying
body movements.
TD can also involve the respiratory muscles of the upper airways,
chest, and diaphragm, causing gasping, stridor, interrupted flow of
speech, paradoxical breathing, dyspnea on exertion, and other
respiratory symptoms similar to those seen in some patients with
primary dystonia and defined as ‘‘dystonic respiratory dysregula-
tion.’’46 TD patients can also exhibit irregular breathing with episodes
of hypoventilation and hyperventilation, audible respiratory noises that
might look very alarming but in most cases do not cause any medical
problem, and other noises, such as continuous humming or
moaning.47
Tardive akathisia (Video 2) is a feeling of inner restlessness involving
the whole body or certain body parts; it is usually uncomfortable to the
patients and sometimes disabling.48 The patients often have repetitive
and stereotypical movements (rocking in a chair, crossing/uncrossing
of legs when sitting, pacing on a spot, shifting weight from one foot to
another when standing, face or scalp touching or scratching) in an
attempt to relieve feelings of restlessness. The movements sometimes
resemble limb and trunk stereotypies of TD without akathisia, but
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tardive stereotypy lacks the sensory component of akathisia. Repetitive
vocalizations such as moaning and grunting are also common features
of akathisia.
Tardive Dystonia (Video 3) can be focal (usually cranial dystonia
affecting jaw, tongue, and facial muscles), segmental, or generalized,
closely resembling idiopathic dystonia but with a few distinctive
features.36,39 Axial TD is typically manifested by opisthotonic posturing,
scoliosis, and retrocollis. Tardive limb dystonia usually presents as
adduction and pronation of arms in the shoulders, extension at elbows,
and flexion of the wrists.
Tardive chorea as the only manifestation of TD is quite rare and
usually accompanies oro-bucco-lingual stereotypy in adult patients
with TD. Because chorea by definition is a random jerk-like
movement, the term ‘‘rhythmic chorea,’’ sometimes applied to tardive
Table 2. Spectrum of Tardive Syndromes
Classic Tardive Dyskinesia Isolated or Predominant Oro-bucco-lingual Dyskinesia (stereotypy)
Tardive stereotypy Seemingly purposeful, repetitive and coordinated movements in the limbs or
trunk (if the face is mainly involved, would be considered as classic TD)
Tardive dystonia Focal, segmental or generalized dystonia (classic features are retrocollis,
opisthotonic trunk posturing, arm extension)
Tardive akathisia Feeling of restlessness, inability to stay still, intense inner urge to move
Tardive tics (tardive tourettism) Clinically indistinguishable from tics in Tourette syndrome but much older age
of onset
Tardive tremor Postural, kinetic, and rest tremor (typically high amplitude and low frequency)
Tardive myoclonus Prominent postural myoclonic jerks in upper extremities
Tardive chorea Usually accompanies classic TD in adult patient
Tardive parkinsonism Rest tremor, bradykinesia, rigidity persisting for months/years after
discontinuation of DRBAs; normal DAT SPECT
Withdrawal emergent syndrome Generalized chorea (no or minimal involvement of oro-bucco-lingual region) in
children after sudden discontinuation of DRBAs; self-limiting condition
Neuroleptic malignant syndrome Fever, rigidity, mental status change, hyperthermia, elevated CK, leukocytosis
Tardive pain Chronic painful oral and genital sensations
Abbreviations: CK, creatine kinase; DAT, dopamine transporter; DRBA, dopamine receptor-blocking agent; SPECT, single photon emission computerized tomography
TD, tardive dyskinesia.
Video 1. Classic Tardive Dyskinesia. A 77-year-old woman developed
symptoms 2 weeks after sudden discontinuation of prochlorperazine 10 mg daily
that she had been taking for a year. The video demonstrates classic oro-bucco-
lingual stereotypy and mild extremity stereotypies.
Video 2. Tardive Akathisia and Tardive Stereotypy. A 34-year-old man
with paranoid schizophrenia treated with haloperidol 10 mg daily for 2.5 years
and lurasidone 80 mg daily for 6 months developed restlessness, inability to stay
still, and abnormal hand movements. The video demonstrates extreme restlessness
and hand-rubbing stereotypies.
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chorea, is not appropriate as many TD patients actually have
stereotypy.
Chorea can be seen in children following sudden withdrawal from a
DRBA as part of the so-called withdrawal emergent syndrome (Video 4).41
This is a self-limiting condition, typically manifesting days or weeks
after DRBA discontinuation as generalized chorea that markedly
differs from the more common tardive stereotypy. The movements in
withdrawal emergent syndrome involve mainly trunk and limbs, and
rarely the oral region, as opposed to classic TD.
Tardive tics, or tardive tourettism (Video 5), is clinically very similar
to motor and phonic tics typically associated with Tourette syndrome,
but the age at onset is usually much older.49
Tardive tremor (Video 5) manifests as postural, kinetic, and resting
oscillatory movement (tremor) in the limbs with a frequency from 3 to
5 Hz and typically of high amplitude. In the absence of parkinsonian
features, it is responsive to dopamine-depleting drugs such as tetrabe-
nazine (TBZ) (see below).50
Tardive myoclonus usually presents as prominent postural spontaneous
or stimulus-sensitive jerk-like movement (myoclonus) in the upper
extremities.51
Tardive parkinsonism is a controversial entity that refers to parkinso-
nian features persisting several months, years, or indefinitely after
cessation of DRBA therapy. Some patients with parkinsonism who do
not improve after DRBA discontinuation might be found to have
evidence of presynaptic dopaminergic deficit as indicated by reduced
density of dopamine transporter (DAT) on 123I-ioflupane single-
photon emission computerized tomography (SPECT), suggesting that
they have an underlying Parkinson’s disease (PD) that became
symptomatic, or unmasked, after DRBA exposure.52,53 There are
three possible scenarios of parkinsonian features in the context of
ongoing or past history of DRBA exposure: 1) parkinsonian features
are present while being treated with DRBAs but resolve within weeks
after its discontinuation (drug-induced parkinsonism); 2) parkinsonian
features are present during DBRA treatment and persist for years after
discontinuation of the offending drug, and DAT SPECT is normal
(tardive parkinsonism); 3) parkinsonian features persist indefinitely
(longer than several months or years after DRBA discontinuation, and
DAT SPECT is abnormal (underlying PD unmasked by exposure to
DRBA). On the other hand, patients with parkinsonism in the context
of ongoing or recent DRBA exposure who have normal 123I-ioflupane
SPECT studies represent true drug-induced parkinsonism or tardive
parkinsonism if the symptoms persist for months or years after
discontinuation of an offending DRBA. A 15-year prospective
population-based study of 2,991 elderly subjects estimated a 3.2-fold
higher risk of developing clinically probable PD in subjects with a
history of exposure to neuroleptics compared to elderly individuals
never exposed to DRBAs, although the mechanism remains unclear.54
Video 3. Tardive Dystonia. A 42-year-old man with mood disorder treated
with ziprasidone 60 mg daily developed mild facial grimacing and tapered off
ziprasidone over 2 weeks followed by worsening and generalization of abnormal
movements. Video demonstrates cervical dystonia with retrocollis and torticollis to
the left, jaw-opening dystonia, blepharospasm, truncal dystonia with opisthotonic
trunk posturing, proximal arms dystonia with arm extension and internal rotation,
and proximal legs dystonia.
Video 4. Withdrawal Emergent Syndrome. An 11-year-old boy with
Tourette syndrome and behavioral problems treated with olanzapine 30 mg daily
and fluphenazine 5 mg daily had all his medications suddenly discontinued, and
1–2 weeks later developed mild piano-playing finger movements with rapid
progression to generalized chorea. The symptoms gradually resolved over the next
2 months with no treatment.
Video 5. Tardive Tics and Tardive Tremor. A 37-year-old man with
history of gastroesophageal reflux disease treated with metoclopramide
(20-30 mg/day) for 9 months developed facial tics and hands tremor (postural and
kinetic) that persisted for 2 years after discontinuation of the medication. The
patient also has left leg stereotypy.
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Tardive gait is another characteristic feature of TD. Gait changes can
vary from ‘‘dancing’’ gait (repetitive short steps on toes followed by a
long stride) to ‘‘duck-like’’ gait (wide-based and unsteady, with short
stride length and mild steppage features).55 TD can also interfere with
normal gait because of axial and arm dystonia.45
Neuroleptic malignant syndrome (NMS) is a rare complication of
neuroleptic treatment that can occur within days to months after the
initial exposure to the DRBA. It typically manifests as a combination
of fever, rigidity, mental status changes, elevated body temperature,
autonomic dysfunction, elevated serum creatine kinase, and leukocy-
tosis, although presence of all symptoms is not required for to make a
diagnosis.43 NMS can be caused by exposure to any DRBA, including
typical and atypical neuroleptics in either stable or escalating doses, or
by sudden withdrawal of dopaminergic medications.43,56 NMS can
range from a relatively mild and self-limiting condition to a life-
threatening disorder.
Tardive pain was described by Ford et al57 in 1994 as a chronic
painful oral and genital sensation in patients exposed to DRBAs who
had TD. Dopamine-depleting medications used to treat motor
symptoms of TD were effective in reducing painful sensations.
Diagnosis and Differential Diagnosis of TD
The diagnosis of TD is based on the patient’s history of exposure to
DRBAs, characteristic clinical presentation, and exclusion or other
conditions with similar phenomenology.
Differential diagnosis of TD should include primary neurological
conditions that can be manifested by various dyskinesias among other
symptoms, such as Huntington’s disease, Wilson’s disease, neuroa-
canthocytosis, prion diseases, neurodegeneration with brain iron
accumulation,58 Sydenham chorea, systemic lupus erythematosus,
antiphospholipid antibody syndrome,59 anti-N-methyl-D-aspartate
receptor encephalitis,60 and other autoimmune diseases.61 Additional
diagnostic work-ups such as neuroimaging, genetic testing, and
metabolic and immune panels might be necessary if historical events
or the course of clinical manifestations suggest the possibility of an
alternative diagnosis besides TD. Orofacial dyskinesia can be observed
in elderly individuals with poor dentition and without any neurological
disorder (edentulous dyskinesia).62 Dyskinesia can occur in patients
taking levodopa or dopamine agonists, but it is a short-lived condition
that remits as soon as the medication wears off.
Tardive tremor needs to be differentiated from tremor in patients
with PD, essential tremor, and dystonic tremor. Lack of other
parkinsonian features (rigidity, bradykinesia, gait abnormality) differ-
entiates tardive tremor from PD. In some more challenging cases,
DAT SPECT might be useful in the differential diagnosis because
there is no presynaptic dopaminergic deficit in tardive tremor or
tardive parkinsonism; therefore, DAT SPECT is expected to be
normal, as opposed to reduced DAT density typically observed in PD.
History of DRBA exposure, lack of family history of tremor, and lack
of sensitivity of tremor to alcohol might help differentiate tardive
tremor from essential tremor. Improvement with TBZ can be observed
in tardive tremor but not with essential or PD-related tremor. In fact,
tremor in PD would be expected to worsen with TBZ. Dystonic tremor
in the limbs is usually irregular, asymmetrical, position-related, and
associated with dystonic posturing of the limb; although dystonia might
be mild and difficult to recognize during the examination. Other drug-
induced tremors, caused by multiple medications including antide-
pressants, neuroleptics, lithium, antiepileptics, amiodarone, beta-
adrenergic agonists, and central nervous system (CNS) stimulants,
should be also considered.63 These tremors usually have higher
frequencies than tardive tremor, are dose dependent, and resolve
within weeks after discontinuation of the offending drug.
Management of TD
Prevention of TD is paramount; therefore, strict selection of patients to
be treated with DRBAs is prudent medical practice. DRBAs should be
avoided whenever possible by choosing alternative medications with lower
potential to cause TD. Furthermore, long-term treatment with DRBAs
should be avoided, but, if absolutely necessary, it should be accompanied
by frequent re-assessments of the need to continue treatment and high
vigilance and monitoring for early symptoms and signs of TD.
The main aspect of TD treatment is removal of a causative drug
whenever possible, but slow taper is recommended as sudden
withdrawal is more likely to precipitate TD or withdrawal emergent
syndrome.41 There is a large body of evidence that supports the notion
that that the sooner the offending medication is discontinued, the more
likely it is that TD will gradually resolve.19 If a patient requires
continuous treatment with antipsychotics, the newer generation of
‘‘atypical’’ neuroleptics, such as quetiapine and clozapine, may be
useful alternatives, although essentially all typical and atypical
neuroleptics carry a risk of TD.6 Restarting or increasing the dose of
a causative DRBA or a similar agent can reduce TD, but this strategy
should be avoided whenever possible and reserved only as an
emergency solution for the most severe cases that require immediate
control of the involuntary movements. High doses of clozapine and
quetiapine have been reported to alleviate TD symptoms,64 but these
drugs should not be used for long-term treatment of TD. It is likely
that atypical neuroleptics in high doses can demonstrate D2 receptor-
blocking quality, acting as typical DRBAs, even causing TD.6
The dopamine-depleting drugs reserpine and TBZ inhibit vesicular
monoamine transporter (VMAT) at the presynaptic membrane of the
nerve terminal; thus exposing monoamines to monoamine oxidase,
which results in depletion of the synaptic pool of monoamines.65–67
Reserpine has slow onset and a prolonged duration of action that
should be taken into consideration while changing the dose. It blocks
both types of VMAT: VMAT1 found peripherally and VMAT2
present in CNS. TBZ has quicker onset and shorter duration of effect.
It selectively inhibits VMAT2 and therefore does not have peripheral
catecholamine-depleting side effects, such as orthostatic hypotension
and gastrointestinal side effects.67 TBZ is currently considered a first-
line agent and the most effective medication to treat persistent and
disabling TD. Previous studies at the Baylor College of Medicine
reported marked or moderate improvement of abnormal movement
intensity and amplitude in up to 95% of patients with TD.67 This
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medication is usually well tolerated; however, with higher doses that
are often needed to control the symptoms of TD, it can cause side
effects such as depression, lethargy, akathisia, and parkinsonism.67
However, all these side effects are dose related, and no documented
case of TBZ-induced TD has been reported. Serious side effects such
as severe hyperthermia, NMS, acute dystonic reaction, and suicide are
rare. Alpha-methylparatyrosine (AMPT) is a competitive inhibitor of
tyrosine hydroxylase, an important enzyme in dopamine synthesis. It is
not very effective as monotherapy but can enhance the antidopami-
nergic effect of dopamine-blocking drugs when used in combination.68
AMPT is rarely used in the treatment of TD.
Other less studied medications may also provide various degrees of
symptomatic improvement in TD, but these observations are based on
small open-label studies and case reports (Table 3). The list of such
medications includes amantadine, possibly acting as a glutamate
receptor-blocking agent,69 GABA agonistic medications, including
benzodiazepines, baclofen, valproic acid,70–73 donepezil acting as a
cholinomimetic,74 lithium,75 antioxidants,76,77 zonisamide,78 vitamin
B6,79 melatonin,80 and zolpidem81 From our experience, zolpidem and
propranolol might be the most effective treatments for tardive akathisia,81
which is often refractory to medical therapy including TBZ; however,
larger studies of the use of zolpidem in TD and tardive akathisia are
required. Anticholinergic medications such as trihexyphenidyl or
ethopropazine can be effective in tardive dystonia,39 but they may
exacerbate classic and other forms of TD. Dopamine agonists and
levodopa are not effective in TD and can exacerbate an underlying
psychiatric disorder. The only exceptions are tardive parkinsonism and
NMS, which are often managed with dopamine agonists if discontinua-
tion of a DRBA alone is not sufficient.
Chemodenervation with botulinum toxin injections into the muscles
causing disabling but focal dyskinesia is also often used in the
treatment of TD, particularly tardive dystonia.82,83 Surgical treatment,
including pallidotomy and pallidal deep brain stimulation, is reserved
for the most severe and medication-resistant cases of TD.84
Withdrawal emergent syndrome is a self-limiting condition that
often does not require treatment.41 For faster recovery or if the
abnormal movements are very uncomfortable for a patient, DRBA can
be reinstituted and tapered off gradually.
Prompt and gradual withdrawal of neuroleptic at the first signs of
NMS is the main intervention to manage this condition. In mild cases,
discontinuation of the offending drug along with supportive sympto-
matic care might be sufficient. In more severe cases of NMS, treatment
with levodopa, dopamine agonists, dantrolene, steroids, and benzo-
diazepines can be used in parallel with intravenous hydration and
careful observation.43 Electroconvulsive therapy may be used in some
drug-resistant and refractory cases of NMS.85
Table 3. Treatment of Tardive Dyskinesia
Medication Starting Daily Dose Daily Dose Range
Slow Taper of an Offending DRBA
Dopamine-depleting medications
Tetrabenazine67 12.5–25 mg 25–200 mg (typical therapeutic dose
50–75 mg)
Reserpine86 0.25 mg 0.75–8 mg
Amantadine86 100 mg 100–300 mg
GABA agonistic medications
Clonazepam86 0.5 mg 1–4 mg
Baclofen73 20–120 mg
Valproic acid73 900–1500 mg
Anticholinergic medications
Trihexyphenidyl87 1 mg 4–20 mg
Less studied/might be effective medications (donepezil, lithium, antioxidants, zonisamide, vitamin B6, melatonin, zolpidem,
propranolol)
Chemodenervation with botulinum toxin injections
Surgical treatment (deep brain stimulation)
Abbreviations: DRBA, dopamine receptor-blocking agent.
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